ResearchA composite F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
ResearchMultiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response
ResearchEA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial)
ResearchDietary supplement beliefs and use patterns among Irish patients with early-stage breast cancer
ResearchCharting cancer's course: revealing the role of diet, exercise, and the microbiome in cancer evolution and immunotherapy response
ResearchCorrelation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)
ResearchMetastatic gastroesophageal cancer in older patients - is this patient cohort represented in clinical trials?
ResearchOne year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre
ResearchPrognostic factors influencing survival following re-resection for isocitrate dehydrogenase (IDH) -wildtype glioblastoma multiforme - Data from a national neuro-oncology registry
ResearchInduction treatment prior to chemoradiotherapy in nasopharyngeal carcinoma: triplet or doublet chemotherapy?